NCT06750783 (Xuezhikang) is a Phase 4 clinical trial of Xuezhikang in Prediabetic State (IGT), sponsored by Beijing Tsinghua Chang Gung Hospital.

Who is sponsoring NCT06750783?

NCT06750783 is sponsored by Beijing Tsinghua Chang Gung Hospital.

What drugs are being tested in NCT06750783?

Interventions in NCT06750783: Xuezhikang, Atorvastatin.

What condition does NCT06750783 study?

NCT06750783 studies Prediabetic State (IGT).

Is NCT06750783 still recruiting?

NCT06750783 is currently recruiting now. Last updated 3 April 2025.

Last reviewed 2025-04-03 · How we verify

NCT06750783: Xuezhikang

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Effects of Xuezhikang and Atorvastatin on Lipid in Patients With Dyslipidemia and Prediabetes

Recruiting now Phase 4 Last updated 3 April 2025

What this trial tests

Phase 4 trial testing Xuezhikang in Prediabetic State (IGT) in 398 participants. Currently enrolling.

Timeline

31 December 2024

Primary endpoint
31 March 2026

31 March 2026

Quick facts

Lead sponsor	Beijing Tsinghua Chang Gung Hospital
Phase	Phase 4
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	398
Start date	31 December 2024
Primary completion	31 March 2026
Estimated completion	31 March 2026
Sites	3 locations across China

Drugs / interventions tested

Xuezhikang
Atorvastatin (atorvastatin) — full drug profile →

Conditions studied

Prediabetic State (IGT) — all drugs for Prediabetic State (IGT) →

Sponsor

Beijing Tsinghua Chang Gung Hospital

Who can join

18 and older, any sex, with Prediabetic State (IGT). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study compares the impact of Xuezhikang and atorvastatin on glucose metabolism to explore the incidence of prediabetes patients developing diabetes after 24 weeks of Xuezhikang use, and by investigating the effect of Xuezhikang on blood glucose fluctuations, discusses the possible mechanisms by which Xuezhikang affects glucose metabolism.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Beijing Tsinghua Chang Gung Hospital trials

Trials by the same sponsor.

NCT07123675 — AI-Assisted Blood Pressure Control During Anesthesia · NA · not yet recruiting
NCT07152496 — Host-Microbe Interactions in Biliary Dilatation · not yet recruiting
NCT07330271 — PTC-Guided Therapy for Peritoneal Mesothelioma · NA · recruiting
NCT07328737 — One vs Three HIPEC Cycles After CRS for Pseudomyxoma Peritonei · NA · recruiting
NCT07044947 — Oteseconazole in the Treatment of Adults With Vulvovaginal Candidiasis（VVC） · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06750783 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Beijing Tsinghua Chang Gung Hospital
Last refreshed: 3 April 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06750783.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing